Stockreport

Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH

Metacrine, Inc.  (MTCR) 
PDF -   Validates therapeutic benefit of combination approaches for a large segment of NASH patients-   Demonstrates additive efficacy results and favorable tolerability pro [Read more]